Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial

Table 1 Patient baseline demographics and disease characteristics and background N[t]RTIs

	All patients N = 313	Treatment-naïve patients N = 295
Male [n (%)]	279 (89)	266 (90)
Age, years [median (range)]	35 (18–72)	34 (18–72)
Race [n (%)]
White	187 (60)	176 (60)
Black or African Heritage	108 (35)	101 (34)
Asian	4 (1)	4 (1)
Other	14 (4)	14 (5)
Log₁₀ VL (HIV-1 RNA copies/ml) [median (range)]	4.8 (2.6–7.0)	4.8 (2.6–7.0)
VL >100,000 HIV-1 RNA copies/ml [n (%)]	131 (42)	122 (41)
CD4⁺ cell count (cells/mm³) [median (range)]	361 (5–1473)	370 (6–1473)
≤200 cells/mm³ [n (%)]	59 (19)	47 (16)
Asymptomatic HIV infection [n (%)]	251 (80)	241 (82)
Co-infection with HBV [n (%)]	5 (2)	5 (2)
Co-infection with HCV [n (%)]	8 (3)	7 (2)
eGFR_CG, ml/min [median (range)]	114 (67–321)	115 (67–321)
Background N[t]RTIs [n (%)]
Emtricitabine/tenofovir	301 (96)	291 (99)
Emtricitabine/tenofovir plus zidovudine	5 (2)	0
Abacavir plus tenofovir	3 (1)	2 (0.7)
Emtricitabine/tenofovir plus abacavir	2 (0.6)	1 (0.3)
Abacavir/lamivudine	1 (0.3)	1 (0.3)
Didanosine plus emtricitabine	1 (0.3)	0

N number of patients; n number of patients with observations; VL viral load; HBV hepatitis B virus; HCV hepatitis C virus; eGFR_CG estimated glomerular filtration rate calculated using the Cockcroft-Gault method; N[t]RTIs nucleoside/tide reverse transcriptase inhibitors.

ISSN: 1742-6405